Securing trust in the global COVID-19 supply chain
From development and delivery to acceptance and administration
COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products.
Forging the links across the value chain
The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies.
Regulation in Life Sciences
Turning complexity into opportunity
Stay ahead of the curve when it comes to regulatory policy in Life Sciences. Here you'll find a range of tools on a variety of topics from around the globe that provide critical insight and advice, helping you to anticipate change and plan ahead.
The future awakens
Life Sciences and Health Care Predictions 2022
The year is 2022. The quantified self is alive and well, digital technologies have transformed the culture of health care and new entrants have disrupted delivery models. These are some of our predictions that, if they come true, will shake up the life sciences and health care industry.
Pharma and the connected patient
How digital technology is enabling patient centricity
New research released by the Deloitte UK Centre for Health Solutions explores how digital technology can help pharma embrace patient centricity to remain relevant, profitable, and to deliver better health outcomes.
Time to care
Securing a future for the hospital workforce in Europe
In light of rising demand, staff shortages and lack of time for hands-on-care, is the current hospital workforce model sustainable? New research released by the Deloitte UK Centre for Health Solutions explores the current state of hospital workforces across Europe and their key challenges.
Identification of Medicinal Products
Identification of Medicinal Products (IDMP) is one the biggest regulatory challenges for all pharmaceutical companies operating in Europe. How can your organisation navigate this journey towards increased patient safety and use it as an opportunity for business transformation?